Clofarabine + Cytarabine intravenous + Methotrexate + Intrathecal (IT) Cytarabine

Phase 2Terminated

1 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Minimal Residual Disease

Conditions

Minimal Residual Disease, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute

Trial Timeline

Aug 1, 2010 → Oct 24, 2012

NCT ID

NCT01158885

About Clofarabine + Cytarabine intravenous + Methotrexate + Intrathecal (IT) Cytarabine

Clofarabine + Cytarabine intravenous + Methotrexate + Intrathecal (IT) Cytarabine is a phase 2 stage product being developed by Sanofi for Minimal Residual Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT01158885. Target conditions include Minimal Residual Disease, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01158885	Phase 2	Terminated	Aug 1, 2010	Oct 24, 2012	Minimal Residual Disease

Competing Products

4 competing products in Minimal Residual Disease

See all competitors

Product	Company	Stage	Hype Score
Pudexacianinium chloride	Astellas Pharma	Phase 2	35
Blinatumomab in combination with donor lymphocyte infusion	Amgen	Phase 2	27
Tislelizumab + Fruquintinib	Takeda Pharmaceutical	Phase 2	42
Rifaximin + rifaximin	Bausch Health	Phase 1/2	26